Acalabrutinib (Calquence) Approved For relapsed or refractory mantle cell lymphoma

Michelle Dawson, MD, AstraZeneca, talks about Acalabrutinib (Calquence) Approved For relapsed or refractory mantle cell lymphoma at Annual Meeting 2018.